379 related articles for article (PubMed ID: 14605865)
1. Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects.
Bolton AE; Peng B; Hubert M; Krebs-Brown A; Capdeville R; Keller U; Seiberling M
Cancer Chemother Pharmacol; 2004 Feb; 53(2):102-6. PubMed ID: 14605865
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects.
Dutreix C; Peng B; Mehring G; Hayes M; Capdeville R; Pokorny R; Seiberling M
Cancer Chemother Pharmacol; 2004 Oct; 54(4):290-4. PubMed ID: 15138710
[TBL] [Abstract][Full Text] [Related]
3. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity.
Gorski JC; Vannaprasaht S; Hamman MA; Ambrosius WT; Bruce MA; Haehner-Daniels B; Hall SD
Clin Pharmacol Ther; 2003 Sep; 74(3):275-87. PubMed ID: 12966371
[TBL] [Abstract][Full Text] [Related]
4. Effect of St John's wort on imatinib mesylate pharmacokinetics.
Frye RF; Fitzgerald SM; Lagattuta TF; Hruska MW; Egorin MJ
Clin Pharmacol Ther; 2004 Oct; 76(4):323-9. PubMed ID: 15470331
[TBL] [Abstract][Full Text] [Related]
5. Metabolism and disposition of imatinib mesylate in healthy volunteers.
Gschwind HP; Pfaar U; Waldmeier F; Zollinger M; Sayer C; Zbinden P; Hayes M; Pokorny R; Seiberling M; Ben-Am M; Peng B; Gross G
Drug Metab Dispos; 2005 Oct; 33(10):1503-12. PubMed ID: 16006570
[TBL] [Abstract][Full Text] [Related]
6. Enzyme induction observed in healthy volunteers after repeated administration of rifapentine and its lack of effect on steady-state rifapentine pharmacokinetics: part I.
Keung A; Reith K; Eller MG; McKenzie KA; Cheng L; Weir SJ
Int J Tuberc Lung Dis; 1999 May; 3(5):426-36. PubMed ID: 10331733
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate.
Borin MT; Chambers JH; Carel BJ; Gagnon S; Freimuth WW
Clin Pharmacol Ther; 1997 May; 61(5):544-53. PubMed ID: 9164416
[TBL] [Abstract][Full Text] [Related]
8. Effect of troglitazone on urinary excretion of 6beta-hydroxycortisol.
Koup JR; Anderson GD; Loi CM
J Clin Pharmacol; 1998 Sep; 38(9):815-8. PubMed ID: 9753209
[TBL] [Abstract][Full Text] [Related]
9. Metronidazole leads to enhanced uptake of imatinib in brain, liver and kidney without affecting its plasma pharmacokinetics in mice.
Tan SY; Kan E; Lim WY; Chay G; Law JH; Soo GW; Bukhari NI; Segarra I
J Pharm Pharmacol; 2011 Jul; 63(7):918-25. PubMed ID: 21635257
[TBL] [Abstract][Full Text] [Related]
10. No relevant effect of ursodeoxycholic acid on cytochrome P450 3A metabolism in primary biliary cirrhosis.
Dilger K; Denk A; Heeg MH; Beuers U
Hepatology; 2005 Mar; 41(3):595-602. PubMed ID: 15726657
[TBL] [Abstract][Full Text] [Related]
11. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis.
Kharasch ED; Walker A; Hoffer C; Sheffels P
Clin Pharmacol Ther; 2004 Nov; 76(5):452-66. PubMed ID: 15536460
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of Saint John's Wort (hypericum perforatum) on the urinary excretion of D-glucaric acid and 6beta-hydroxycortisol in healthy volunteers.
Bauer S; Störmer E; Kerb R; Johne A; Brockmöller J; Roots I
Eur J Clin Pharmacol; 2002 Dec; 58(9):581-5. PubMed ID: 12483450
[TBL] [Abstract][Full Text] [Related]
13. Urinary excretion of 6 beta-hydroxycortisol as an in vivo marker for CYP3A induction: applications and recommendations.
Kovacs SJ; Martin DE; Everitt DE; Patterson SD; Jorkasky DK
Clin Pharmacol Ther; 1998 Jun; 63(6):617-22. PubMed ID: 9663175
[TBL] [Abstract][Full Text] [Related]
14. The influence of St. John's wort on the pharmacokinetics and protein binding of imatinib mesylate.
Smith P; Bullock JM; Booker BM; Haas CE; Berenson CS; Jusko WJ
Pharmacotherapy; 2004 Nov; 24(11):1508-14. PubMed ID: 15537555
[TBL] [Abstract][Full Text] [Related]
15. The use of human hepatocyte cultures to study the induction of cytochrome P-450.
Kostrubsky VE; Ramachandran V; Venkataramanan R; Dorko K; Esplen JE; Zhang S; Sinclair JF; Wrighton SA; Strom SC
Drug Metab Dispos; 1999 Aug; 27(8):887-94. PubMed ID: 10421615
[TBL] [Abstract][Full Text] [Related]
16. Effect of rifampin on the pharmacokinetics and pharmacodynamics of gliclazide.
Park JY; Kim KA; Park PW; Park CW; Shin JG
Clin Pharmacol Ther; 2003 Oct; 74(4):334-40. PubMed ID: 14534520
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults.
Menon-Andersen D; Mondick JT; Jayaraman B; Thompson PA; Blaney SM; Bernstein M; Bond M; Champagne M; Fossler MJ; Barrett JS
Cancer Chemother Pharmacol; 2009 Jan; 63(2):229-38. PubMed ID: 18398615
[TBL] [Abstract][Full Text] [Related]
18. Effects of a concomitant single oral dose of rifampicin on the pharmacokinetics of pravastatin in a two-phase, randomized, single-blind, placebo-controlled, crossover study in healthy Chinese male subjects.
Deng S; Chen XP; Cao D; Yin T; Dai ZY; Luo J; Tang L; Li YJ
Clin Ther; 2009 Jun; 31(6):1256-63. PubMed ID: 19695392
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of imatinib mesylate in end stage renal disease. A case study.
Pappas P; Karavasilis V; Briasoulis E; Pavlidis N; Marselos M
Cancer Chemother Pharmacol; 2005 Oct; 56(4):358-60. PubMed ID: 15883819
[TBL] [Abstract][Full Text] [Related]
20. Effect of rifampin on the pharmacokinetics and pharmacodynamics of prasugrel in healthy male subjects.
Farid NA; Jakubowski JA; Payne CD; Li YG; Jin Y; Ernest II CS; Winters KJ; Brandt JT; Salazar DE; Small DS
Curr Med Res Opin; 2009 Aug; 25(8):1821-9. PubMed ID: 19530977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
